Price Action Alert: Could Five Prime Therapeutics Inc Skyrocket Even More? The Stock Just Made All Time High

Price Action Alert: Could Five Prime Therapeutics Inc Skyrocket Even More? The Stock Just Made All Time High

The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) reached all time high today, Nov, 24 and still has $64.53 target or 7.00% above today’s $60.31 share price. This indicates more upside for the $1.71 billion company. This technical setup was reported by If the $64.53 PT is reached, the company will be worth $119.70M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 3.20% or $1.87 on November 23, hitting $60.31. About 302,473 shares traded hands. Five Prime Therapeutics Inc (NASDAQ:FPRX) has risen 21.20% since April 22, 2016 and is uptrending. It has outperformed by 15.79% the S&P500.

Analysts await Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings on March, 9. They expect $-0.51 earnings per share, down 104.80% or $11.14 from last year’s $10.63 per share. After $-0.72 actual earnings per share reported by Five Prime Therapeutics Inc for the previous quarter, Wall Street now forecasts -29.17% EPS growth.

Five Prime Therapeutics Inc (NASDAQ:FPRX) Ratings Coverage

Out of 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Five Prime Therapeutics has been the topic of 9 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The rating was maintained by Credit Suisse with “Outperform” on Friday, March 11. On Friday, August 21 the stock rating was upgraded by Zacks to “Sell”. The firm earned “Sell” rating on Tuesday, August 11 by Zacks. The stock has “Outperform” rating given by Oppenheimer on Monday, October 19. Citigroup initiated Five Prime Therapeutics Inc (NASDAQ:FPRX) on Tuesday, October 25 with “Buy” rating. The stock has “Buy” rating given by Citigroup on Friday, July 31. The rating was initiated by BMO Capital Markets on Tuesday, April 12 with “Market Perform”. The stock of Five Prime Therapeutics Inc (NASDAQ:FPRX) has “Outperform” rating given on Friday, December 4 by Wells Fargo.

According to Zacks Investment Research, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.”

Insitutional Activity: The institutional sentiment decreased to 1.15 in 2016 Q2. Its down 1.14, from 2.29 in 2016Q1. The ratio is negative, as 15 funds sold all Five Prime Therapeutics Inc shares owned while 34 reduced positions. 47 funds bought stakes while 65 increased positions. They now own 24.20 million shares or 3.63% more from 23.35 million shares in 2016Q1.
Blackrock Gru Ltd has 0% invested in the company for 18,147 shares. Price T Rowe Md accumulated 39,045 shares or 0% of the stock. Hbk Invests Limited Partnership reported 74,804 shares or 0.02% of all its holdings. Eam Investors Lc last reported 20,919 shares in the company. Morgan Stanley has 9,942 shares for 0% of their US portfolio. Virginia Retirement Sys Et Al reported 26,500 shares or 0.02% of all its holdings. Clarivest Asset Management Limited Liability last reported 0.05% of its portfolio in the stock. Aqr Lc accumulated 0.01% or 120,122 shares. Moreover, Baker Bros Advsrs L P has 0.01% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 19,247 shares. Gotham Asset Ltd Liability owns 241,475 shares or 0.12% of their US portfolio. Moreover, Blackrock Advsrs Lc has 0% invested in Five Prime Therapeutics Inc (NASDAQ:FPRX) for 42,726 shares. Envestnet Asset Management last reported 1,047 shares in the company. Amer Group holds 15,532 shares or 0% of its portfolio. Tudor Investment Corp Et Al has invested 0.01% of its portfolio in Five Prime Therapeutics Inc (NASDAQ:FPRX). Schroder Invest Mgmt Group Inc has 15,198 shares for 0% of their US portfolio.

Insider Transactions: Since July 27, 2016, the stock had 0 insider purchases, and 6 insider sales for $1.15 million net activity. $22,100 worth of Five Prime Therapeutics Inc (NASDAQ:FPRX) was sold by RINGO WILLIAM R on Thursday, September 1. Another trade for 12,195 shares valued at $603,653 was sold by Jensen Peder.

FPRX Company Profile

Five Prime Therapeutics, Inc. (Five Prime), incorporated on December 20, 2001, is a clinical-stage biotechnology firm focused on discovering and developing protein therapeutics. The Firm has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Firm seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment